LMAT stock forecast, quote, news & analysis

Key Takeaways

• LeMaitre Vascular reported Q4 2025 revenue of $64.5 million, up 16% year-over-year, beating estimates with EPS of $0.68.
• Full-year 2025 sales grew 14% organically, driving 30% operating income expansion amid higher gross margins.
• 2026 guidance projects 12% organic sales growth to $280 million midpoint, with adjusted EPS of $2.91.
• Company raised quarterly dividend 25% to $0.25 per share and authorized $100 million share repurchase.
• Stock surged over 20% post-earnings, reflecting investor optimism despite a disclosed January cyber incident with minimal impact.
• Analysts raised price targets, maintaining buy ratings on strong international growth in grafts and shunts.

Current Market Snapshot

LeMaitre Vascular (LMAT) stock has shown robust momentum in recent trading sessions, propelled by superior quarterly results and upbeat guidance that outpaced consensus expectations. Shares reached new 52-week highs amid elevated volume, underscoring confidence in the company's vascular device portfolio and operational leverage. Gross margins expanded notably due to pricing power and efficiencies, while international sales, particularly in EMEA and APAC, provided a key growth engine. Trading around a forward P/E reflecting premium valuation, LMAT benefits from a strong balance sheet with substantial cash reserves supporting capital returns and potential M&A. Volatility remains moderate, with focus shifting to execution amid medtech sector dynamics.

Trending AI Robots

Tickeron’s Trending AI Robots page features a curated selection of the platform's top-performing AI trading bots, handpicked by advanced algorithms for their suitability in prevailing market conditions. Tickeron offers over 25 AI trading bots that analyze thousands of tickers across stocks, ETFs, and crypto, employing diverse strategies like technical and fundamental analysis on timeframes from 5 minutes to daily. These bots deliver real-time signals for copy trading via Signal, Virtual, or Brokerage Agents, with no minimum balances required for signals. Highlighted trending bots boast impressive stats, including annualized returns up to +251%, win rates ranging from 55% to 95%, and profit factors exceeding 20 in sectors like semiconductors, aerospace, and biotech. For instance, bots targeting industrials or ETFs show average trades lasting 2-10 days with profit-to-drawdown ratios up to 11.6. This dynamic leaderboard spotlights bots outperforming the S&P 500 amid current volatility, empowering traders with data-driven insights. Explore the page to identify bots aligning with your risk tolerance and portfolio goals.

Recent Developments Driving LMAT Price Action

LeMaitre Vascular's stock experienced a sharp rally in recent weeks, surging over 20% to new 52-week highs following the release of stellar Q4 2025 results on February 25, 2026. The company posted revenue of $64.5 million, a 16% increase (15% organic) from $55.7 million a year earlier, surpassing analyst estimates of $62.98 million. Diluted EPS climbed 39% to $0.68, topping consensus by $0.01, fueled by a 71.7% gross margin—up 240 basis points—and 47% operating income growth to $18.8 million (29% margin). Key product lines shone: grafts up 27%, valvulotomes 20%, and carotid shunts 18%, with geographic strength in EMEA (+29%) and APAC (+20%). Full-year 2025 sales hit $249.6 million (+14% organic), with operating income rising 30% to $67.9 million.

Management attributed gains to higher average selling prices (9% for the year), unit volume growth, and international Artegraft expansion, now direct in 32 countries. Capital allocation drew praise: a 25% dividend hike to $0.25 quarterly (payable March 26) and a new $100 million share repurchase program through February 2027. 2026 guidance further catalyzed the move, forecasting Q1 sales of $65.6-$67.6 million (+11%), full-year $276-$284 million (+12% organic), gross margin 72.1%, and EPS $2.81-$3.01 (midpoint $2.91, +16%). These figures exceed Street estimates, signaling sustained leverage.

Analyst reactions reinforced bullish sentiment. Barrington Research lifted its target to $105 from $95 (Outperform), Roth Capital to $117 from $108 (Buy), Citizens to $118 (Outperform), and others like Sidoti and Lake Street reaffirmed buys. Consensus target nears $109, implying upside.

Offsetting some enthusiasm, management disclosed a January 2026 cyber incident impacting certain systems, though critical operations were restored swiftly with "minimal to no disruption" to sales or manufacturing. The company views it as non-material, with insurance coverage and impacts baked into guidance; review ongoing per 10-K risks. No prior major news disrupted the pre-earnings build-up, where shares consolidated near prior highs amid broader medtech recovery. The earnings beat linked directly to the breakout, with volume spiking on positive guidance and returns, though valuation at ~40x forward earnings tempers gains somewhat.

2026 Outlook and Key Factors to Monitor

As LeMaitre Vascular navigates 2026, investors should track execution of its 12% organic sales growth target, driven by pricing discipline (e.g., 8% U.S. list increase), Artegraft international rollout, and sales force expansion to 170-180 reps. Gross margin stability at 72.1% hinges on manufacturing efficiencies amid facility transfers (RestoreFlow to Burlington, Chicago RFA consolidation), with CapEx elevated at ~$11 million. Operating leverage could yield 21% adjusted income growth if unit volumes in grafts, valvulotomes, and shunts persist, supported by EMEA/APAC momentum.

Risks include the ongoing cyber incident review, potential insurance shortfalls, or regulatory hurdles like FDA warning at North Brunswick and MDR/UKCA recertifications in Europe/China demanding more clinical data. Competitive pressures in peripheral vascular devices, supply chain dynamics, and macroeconomic factors affecting hospital spending warrant attention. Opportunities lie in $359 million cash for M&A, biologics expansion, and capital returns via buybacks/dividends. Balanced positioning in a growing medtech niche positions LMAT for steady progress, contingent on risk mitigation.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.